VK2735
VK2735 is a dual agonist of the GIP receptor and GLP-1 receptor,[1] with a similar mechanism of action to that of tirzepatide ‒ a drug for diabetes.[1] It can be injected via human skin.[1] It is made by the pharmaceutical company Viking Therapeutics.[1]
References
- ↑ 1.0 1.1 1.2 1.3
- Mariam E Sunny, Bhanvi Satija (2024-02-27). "Viking Therapeutics notches success with weight-loss drug trial, shares double". Reuters. Retrieved 2024-03-09.
- Goldenberg, Ronald M.; Teoh, Hwee; Verma, Subodh (2023-08-21). "Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data". Current Opinion in Cardiology. Ovid Technologies (Wolters Kluwer Health). 38 (6): 539–545. doi:10.1097/hco.0000000000001084. ISSN 0268-4705. PMID 37792556.
{{cite journal}}: Check|pmid=value (help) - Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists". Obesity Reviews. 25 (3): e13663. doi:10.1111/obr.13663. ISSN 1467-7881. PMID 37968541.
{{cite journal}}: Check|pmid=value (help)
